The effectiveness of 13-valent pneumococcal vaccine against community acquired pneumonia in young children: a systematic review and meta-analysis

Q4 Medicine
N. Revenco, A. Balanuta, Dina Bujor, A. Horodisteanu-Banuh, O. Cirstea
{"title":"The effectiveness of 13-valent pneumococcal vaccine against community acquired pneumonia in young children: a systematic review and meta-analysis","authors":"N. Revenco, A. Balanuta, Dina Bujor, A. Horodisteanu-Banuh, O. Cirstea","doi":"10.37897/rjp.2022.3.5","DOIUrl":null,"url":null,"abstract":"Objective. The present meta-analysis study aimed to evaluate the effectiveness of 13-valent pneumococcal conjugate vaccine (PCV) in reducing the morbidity from pneumonia among children under 5 years old. Material and methods. Cochrane and Medline electronic databases were systematically searched for studies reporting effectiveness of 13-valent pneumococcal conjugate vaccine against pneumonia among children of the foreseen age group. To assess the effect measure, we used the odds ratio (OR) with 95% confidence intervals (95% CI) for dichotomous outcomes. The heterogeneity of the studies was assessed using I2 and Chi2 statistics. Outcomes. The meta-analysis found a non-significant association between vaccinated children and the development of community-acquired pneumonia (OR=0.50; CI 95%: 0.44-0.57; Chi2=6.07; I2=18%). Vaccine effectiveness (VE) of 13-valent PCV was calculated as (1 – Mantel-Haenszel OR in vaccinated children compared to unvaccinated children) x100%. Thus, the VE of PCV 13 valent was estimated to be about 50%, according to the meta-analysis of the included studies. Conclusions. Our study showed that the group of vaccinated children experienced 50% fewer cases of pneumonia than they would have had if they had not been vaccinated. These data bring additional evidence that vaccination is an effective strategy to prevent community acquired pneumonia in young children.","PeriodicalId":33512,"journal":{"name":"Revista Romana de Pediatrie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Romana de Pediatrie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37897/rjp.2022.3.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective. The present meta-analysis study aimed to evaluate the effectiveness of 13-valent pneumococcal conjugate vaccine (PCV) in reducing the morbidity from pneumonia among children under 5 years old. Material and methods. Cochrane and Medline electronic databases were systematically searched for studies reporting effectiveness of 13-valent pneumococcal conjugate vaccine against pneumonia among children of the foreseen age group. To assess the effect measure, we used the odds ratio (OR) with 95% confidence intervals (95% CI) for dichotomous outcomes. The heterogeneity of the studies was assessed using I2 and Chi2 statistics. Outcomes. The meta-analysis found a non-significant association between vaccinated children and the development of community-acquired pneumonia (OR=0.50; CI 95%: 0.44-0.57; Chi2=6.07; I2=18%). Vaccine effectiveness (VE) of 13-valent PCV was calculated as (1 – Mantel-Haenszel OR in vaccinated children compared to unvaccinated children) x100%. Thus, the VE of PCV 13 valent was estimated to be about 50%, according to the meta-analysis of the included studies. Conclusions. Our study showed that the group of vaccinated children experienced 50% fewer cases of pneumonia than they would have had if they had not been vaccinated. These data bring additional evidence that vaccination is an effective strategy to prevent community acquired pneumonia in young children.
13价肺炎球菌疫苗对幼儿社区获得性肺炎的有效性:系统综述和荟萃分析
客观的本荟萃分析研究旨在评估13价肺炎球菌结合疫苗(PCV)在降低5岁以下儿童肺炎发病率方面的有效性。材料和方法。系统地检索了Cochrane和Medline电子数据库中报告13价肺炎球菌结合疫苗对预期年龄组儿童肺炎有效性的研究。为了评估效果测量,我们使用优势比(OR)和95%置信区间(95%CI)来评估二分结果。使用I2和Chi2统计数据评估研究的异质性。结果。荟萃分析发现,接种疫苗的儿童与社区获得性肺炎的发展之间没有显著关联(OR=0.50;CI95%CI:0.44-0.57;Chi2=6.07;I2=18%)。13价PCV的疫苗有效性(VE)计算为(接种疫苗儿童与未接种疫苗儿童的Mantel Haenszel OR)x100%。因此,根据纳入研究的荟萃分析,PCV 13价的VE估计约为50%。结论。我们的研究表明,与未接种疫苗的儿童相比,接种疫苗的这组儿童的肺炎病例减少了50%。这些数据进一步证明,接种疫苗是预防幼儿社区获得性肺炎的有效策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
15
审稿时长
4 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信